G1 Therapeutics to Provide Third Quarter 2021 Financial Results and Business Update on November 3, 2021

Rhea-AI Summary

G1 Therapeutics, Inc. (GTHX) has announced a webcast and conference call to discuss its third-quarter 2021 corporate and financial update, scheduled for November 3, 2021, at 8:30 a.m. ET. The company focuses on developing therapies for cancer treatment, including its first commercial product, COSELA™ (trilaciclib). G1 is pursuing a tumor-agnostic development strategy for COSELA, targeting various solid tumors such as colorectal, breast, lung, and bladder cancers. Interested parties can access the call via phone or through the company's website.

Positive

• Company scheduled a Q3 financial update, indicating ongoing operations.
• G1 Therapeutics focuses on cancer therapies with a strong clinical pipeline.
• COSELA™ is being evaluated in multiple solid tumors, enhancing growth potential.

Negative

• None.

RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2021 on Wednesday, November 3, 2021 at 8:30 a.m. ET.

The live call may be accessed by dialing (866) 763-6020 (domestic) or (210) 874-7713 (international) and entering the conference code: 4404009. The live and archived webcast will be available on the Events & Presentations page of http://www.g1therapeutics.com.

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

G1 Therapeutics™ and the G1 Therapeutics logo are trademarks of G1 Therapeutics, Inc.

G1 Therapeutics Contacts:

Will Roberts
Vice President
Investor Relations and Corporate Communications
(919) 907-1944
wroberts@g1therapeutics.com

Rebecca Levine
Director, Corporate Communications and Public Relations
(919) 667-8711
rlevine@g1therapeutics.com  

FAQ

When is G1 Therapeutics' Q3 2021 earnings call?

G1 Therapeutics' Q3 2021 earnings call is scheduled for November 3, 2021, at 8:30 a.m. ET.

What is the focus of G1 Therapeutics?

G1 Therapeutics focuses on developing and commercializing therapies for cancer, including its product COSELA™.

What is COSELA and what tumors is it targeting?

COSELA™ (trilaciclib) is being evaluated for various solid tumors, including colorectal, breast, lung, and bladder cancers.